ELYBRIO Trademark

Trademark Overview

On Friday, February 25, 2022, a trademark application was filed for ELYBRIO with the United States Patent and Trademark Office. The USPTO has given the ELYBRIO trademark a serial number of 97285540. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Monday, March 31, 2025. This trademark is owned by Amylyx Pharmaceuticals, Inc.. The ELYBRIO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of neurological diseases and neurodegenerative diseases
elybrio

General Information

Serial Number97285540
Word MarkELYBRIO
Filing DateFriday, February 25, 2022
Status733 - FOURTH EXTENSION - GRANTED
Status DateMonday, March 31, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 1, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of neurological diseases and neurodegenerative diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 3, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAmylyx Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02141
Party NameAmylyx Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02141

Trademark Events

Event DateEvent Description
Friday, September 23, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 1, 2022NEW APPLICATION ENTERED
Thursday, March 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, September 23, 2022ASSIGNED TO EXAMINER
Wednesday, October 12, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sunday, March 12, 2023EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, November 1, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 1, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, November 14, 2022EXTENSION OF TIME TO OPPOSE RECEIVED
Friday, April 5, 2024SOU EXTENSION 2 FILED
Tuesday, April 25, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, October 23, 2023SOU TEAS EXTENSION RECEIVED
Monday, October 23, 2023SOU EXTENSION 1 FILED
Monday, October 23, 2023SOU EXTENSION 1 GRANTED
Wednesday, October 25, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 5, 2024SOU EXTENSION 2 GRANTED
Friday, April 5, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 15, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2024SOU EXTENSION 3 GRANTED
Tuesday, October 15, 2024SOU EXTENSION 3 FILED
Monday, March 31, 2025SOU TEAS EXTENSION RECEIVED
Saturday, April 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 31, 2025SOU EXTENSION 4 FILED
Monday, March 31, 2025SOU EXTENSION 4 GRANTED
Tuesday, April 1, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 15, 2025SOU TEAS EXTENSION RECEIVED

Related Keywords

elybrio diseases neurodegenerative neurological treatment preparations pharmaceutical